Cetuximab plus irinotecan administered biweekly with reduced infusion time to heavily pretreated patients with metastatic colorectal cancer and related RAS and BRAF mutation status-Reference-Cited by-同舟云学术

Cetuximab plus irinotecan administered biweekly with reduced infusion time to heavily pretreated patients with metastatic colorectal cancer and related RAS and BRAF mutation status

Published:2020-12-30 Issue:10 Volume:148 Page:2542-2556
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Jensen Benny Vittrup¹^ORCID,Schou Jakob V.¹,Yilmaz Mette²,Johannesen Helle H.³,Skougaard Kristin¹,Linnemann Dorte⁴,Hogdall Estrid V.⁴⁵,Larsen Finn O.¹,Johansen Julia S.¹⁶⁵,Pfeiffer Per⁷,Nielsen Dorte L.¹

Affiliation:

1. Department of Oncology Herlev and Gentofte Hospital, Copenhagen University Hospital Copenhagen Denmark

2. Department of Oncology Aalborg University Hospital Aalborg Denmark

3. Department of Radiology Herlev and Gentofte Hospital, Copenhagen University Hospital Copenhagen Denmark

4. Department of Pathology Herlev and Gentofte Hospital, Copenhagen University Hospital Copenhagen Denmark

5. Department of Clinical Medicine, Faculty of Health and Medical Sciences University of Copenhagen Copenhagen Denmark

6. Department of Medicine Herlev and Gentofte Hospital, Copenhagen University Hospital Copenhagen Denmark

7. Department of Oncology Odense University Hospital Odense Denmark

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.33448

Reference46 articles.

1. Chemoprevention of Breast Cancer: A Model for Change

2. Cetuximab (IMC‐C225) plus irinotecan (CPT‐11) is active in CPT‐11‐refractary colorectal cancer (CRC) that expresses epidermal growth factor receptor(EGFR);Saltz L;Proc Am Soc Clin Oncol,2001

3. Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

4. Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil

5. Cetuximab Plus Irinotecan in Heavily Pretreated Metastatic Colorectal Cancer Progressing on Irinotecan: MABEL Study

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CXCL10 mediates CD8+ T cells to facilitate vessel normalization and improve the efficacy of cetuximab combined with PD-1 checkpoint inhibitors in colorectal cancer;Cancer Letters;2023-07

2. Rescue of Low-Yield DNA Samples for Next-Generation Sequencing Using Vacuum Centrifugal Concentration in a Clinical Workflow;Reports;2023-05-23

3. Role of ferroptosis in colorectal cancer;World Journal of Gastrointestinal Oncology;2023-02-15

4. Aspirin promotes RSL3-induced ferroptosis by suppressing mTOR/SREBP-1/SCD1-mediated lipogenesis in PIK3CA-mutant colorectal cancer;Redox Biology;2022-09

5. Cetuximab promotes RSL3-induced ferroptosis by suppressing the Nrf2/HO-1 signalling pathway in KRAS mutant colorectal cancer;Cell Death & Disease;2021-11